|
|
|
| Portal stent with endovascular brachytherapy improves the efficacy of TACE for hepatocellular carcinoma with main portal vein tumor thrombus |
| Tian Li, Chong Liu, Jin-Tong He, Kai-Da Sui, Zhou-Bo Zhang, Duo Hong, Hong-Ying Su, Hai-Bo Shao ∗ |
Department of Interventional Radiology, the First Hospital of China Medical University, Shenyang 110001, China
∗ Corresponding author.
E-mail address: haiboshao@aliyun.com (H.-B. Shao). |
|
|
|
|
Abstract Hepatocellular carcinoma (HCC) with portal vein tumor thrombus (PVTT) yields poor prognosis with a median overall survival (OS) of 2.7–4 months [1]. Once PVTT develops in the main portal vein, the sudden appearance of portal hypertension often leads to fatal complications, including esophagogastric variceal hemorrhage, refractory ascites, and liver failure. Transarterial chemoembolization (TACE) has been recommended for advanced HCC patients by China Liver Cancer Group due to its benefit of OS compared with using sorafenib alone [2]. For the treatment of PVTT, portal stent with endovascular iodine-125 brachytherapy (PSEIB) was recently reported to be effective because it relieved portal hypertension rapidly and controlled PVTT effectively with an improved OS of 9.3–12.5 months [3,4]. The combination of PSEIB and TACE had been applied in some studies [3,4]. Nevertheless, these studies failed to demonstrate the effect of PSEIB on TACE results. Herein we aimed to present a case how PSEIB improves the efficacy of TACE for HCC patients with main PVTT.
|
|
|
|
|
|
|
|
|
2020, Vol. 19 
